Fluconazole
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
A first-generation triazole antifungal with excellent activity against most Candida species (except C. krusei and some C. glabrata) and Cryptococcus neoformans. Used for vulvovaginal candidiasis (single dose), oropharyngeal and esophageal candidiasis, candidemia, cryptococcal meningitis (induction and long-term suppression in HIV patients), and prophylaxis in immunocompromised patients. Excellent oral bioavailability and CNS penetration.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
A first-generation triazole antifungal with excellent activity against most Candida species (except C. NutriStack rates the supporting evidence as strong. Common adult dosing is Vaginal candidiasis: 150 mg single dose; oropharyngeal: 200 mg day 1, then 100 mg daily x 7-14 days; esophageal: 200-400 mg daily; systemic: 400-800 mg daily (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: treats vulvovaginal candidiasis (single 150 mg dose), treats oropharyngeal and esophageal candidiasis, treats candidemia and invasive candidiasis. 10 sources indexed (2013–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Selectively inhibits fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase (CYP51A1), which converts lanosterol to ergosterol. Ergosterol is an essential component of fungal cell membranes (analogous to cholesterol in mammalian membranes). Depletion of ergosterol and accumulation of toxic methylated sterol intermediates disrupts membrane integrity, permeability, and function, leading to growth inhibition. Primarily fungistatic against Candida but fungicidal against Cryptococcus.3
Dosing & protocol.
Excellent oral bioavailability (>90%), not significantly affected by food or gastric pH. Oral and IV doses are interchangeable. Moderate CYP2C9, CYP2C19, and CYP3A4 inhibitor, significant drug interactions possible.2
Full safety detail.
Side effects
- Nausea
- Headache
- Abdominal pain
- Diarrhea
- Elevated liver enzymes (hepatotoxicity with prolonged high-dose use)
- QT prolongation (dose-dependent)
- Skin rash (rarely Stevens-Johnson syndrome)
Contraindications
- Known hypersensitivity to fluconazole or other azole antifungals1,2
- Concomitant use with terfenadine (when fluconazole >=400 mg/day), cisapride, erythromycin, pimozide, or quinidine (QT prolongation risk)1,2
- Pregnancy (category D for chronic high-dose use, associated with craniofacial and skeletal defects)2
- Severe hepatic disease (weigh risk vs benefit)3,6
- Concomitant use with drugs metabolized by CYP2C9 or CYP3A4 with narrow therapeutic indices (warfarin, phenytoin, cyclosporine)
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
7- 1Pediatric Coccidioidal Meningitis: A Systematic Review and Proportional Synthesis of Cases Reported in the Fluconazole Era (2000-2025)PMIDDe la Cerda-Vargas MF, Navarro-Dominguez P, Meza-Mata E et al. · Journal of fungi (Basel, Switzerland) · 2025
De la Cerda-Vargas MF, Navarro-Dominguez P, Meza-Mata E et al.. Pediatric Coccidioidal Meningitis: A Systematic Review and Proportional Synthesis of Cases Reported in the Fluconazole Era (2000-2025). Journal of fungi (Basel, Switzerland). 2025
- 2Risk of congenital malformations and miscarriages following maternal use of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis.PMIDLatour M, Vauzelle C, Elefant E et al. · European Journal of Epidemiology · 2024
Meta-analysis found low-dose fluconazole (150 mg) in first trimester was not significantly associated with major congenital malformations, but high-dose or prolonged use may increase risk of specific birth defects; vaginal azoles remain preferred in pregnancy.
- 3A meta-analysis of fluconazole for the prevention of invasive fungal infection in preterm infants.PMIDWang XL, Ma Y, Wang SH et al. · American Journal of Translational Research · 2021
Meta-analysis found fluconazole prophylaxis significantly reduced the incidence of invasive fungal infections in very low birth weight and preterm infants without increasing resistance or significant adverse effects.
- 4Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literaturePMIDBudani MC, Fensore S, Di Marzio M et al. · Reproductive toxicology (Elmsford, N.Y.) · 2021
Budani MC, Fensore S, Di Marzio M et al.. Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literature. Reproductive toxicology (Elmsford, N.Y.). 2021
- 5A systematic review of fluconazole resistance in clinical isolates of Cryptococcus speciesPMIDBongomin F, Oladele RO, Gago S et al. · Mycoses · 2018
Bongomin F, Oladele RO, Gago S et al.. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018
- 6Fluconazole prophylaxis in preterm infants: a systematic reviewPMIDRios JFDS, Camargos PAM, Corrêa LP et al. · The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2017
Rios JFDS, Camargos PAM, Corrêa LP et al.. Fluconazole prophylaxis in preterm infants: a systematic review. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2017
- 7Safety of fluconazole in paediatrics: a systematic reviewPMIDEgunsola O, Adefurin A, Fakis A et al. · European journal of clinical pharmacology · 2013
Egunsola O, Adefurin A, Fakis A et al.. Safety of fluconazole in paediatrics: a systematic review. European journal of clinical pharmacology. 2013
Reference material
3- 8Pappas PG et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by IDSA. Clin Infect Dis. 2016.Source linkedPMID
- 9Perfect JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by IDSA. Clin Infect Dis. 2010.Source linkedPMID
- 10Sobel JD et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998.Source linkedPMID
Common questions.
Quick answers about Fluconazole, drawn from the data on this page.
What is Fluconazole?
A first-generation triazole antifungal with excellent activity against most Candida species (except C. krusei and some C. glabrata) and Cryptococcus neoformans. Used for vulvovaginal candidiasis (single dose), oropharyngeal and esophageal candidiasis, candidemia, cryptococcal meningitis (induction and long-term suppression in HIV patients), and prophylaxis in immunocompromised patients. Excellent oral bioavailability and CNS penetration.
What is Fluconazole used for?
Commonly cited benefits of Fluconazole include: Treats vulvovaginal candidiasis (single 150 mg dose); Treats oropharyngeal and esophageal candidiasis; Treats candidemia and invasive candidiasis; Treats cryptococcal meningitis; Prophylaxis in immunocompromised patients. NutriStack rates the overall evidence as strong.
What is a typical dose of Fluconazole?
A typical adult dose of Fluconazole is Vaginal candidiasis: 150 mg single dose; oropharyngeal: 200 mg day 1, then 100 mg daily x 7-14 days; esophageal: 200-400 mg daily; systemic: 400-800 mg daily (as prescribed by your physician). The commonly recommended form is Oral tablets, oral suspension, or IV. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Fluconazole?
Reported side effects include nausea, headache, abdominal pain, diarrhea, elevated liver enzymes (hepatotoxicity with prolonged high-dose use), qt prolongation (dose-dependent). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Fluconazole?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Fluconazole in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.